Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

Tryptamine TherapeuticsASX: TYP

Also known as: Tryp Therapeutics

2 Drug Candidates

Australian biotech (formerly Tryp Therapeutics, relisted on ASX following Exopharm acquisition in May 2024) developing psilocybin and psilocin formulations for treatment-resistant conditions. TRP-8802 (oral psilocybin) completed Phase 2a trials for fibromyalgia and binge eating disorder. TRP-8803 (IV psilocin) has entered Phase 1 with first-in-human dosing.

Drug Pipeline

2

TRP-8802

Psilocybin
Phase II
FibromyalgiaEating Disorders

Oral psilocybin. Phase 2a trials completed for fibromyalgia and binge eating disorder (BED).

TRP-8803

Phase I

IV psilocin formulation. First-in-human dosing initiated. Under investigation for treatment-resistant psychiatric and pain conditions.

Quick Facts

Type
Public Biotech
Ticker
ASX: TYP
Lead Stage
Phase II
Website
Visit